The significant rise in new GLP-1 RA prescriptions between 2011 and 2023 saw a doubling in the proportion written for obesity and a decline in those for T2D.
Tirzepatide-treated participants were 3 times more likely than those treated with semaglutide to reach weight loss of 15% or greater, the head-to-head study found.